Webinar by BIS Research on Precision Oncology Biomarkers

Precision Oncology
Biomarkers: State-
of-the-Art
Technologies and
Emerging Strategies
Emerging Tech Webinar
May 2023

2
Speakers
Dr. Michael R. Rossi
Vice President, ConcertAI
Dr. Shibicharkravarthy Kannan
CEO, Oncophenomics
Nitish Kumar Singh
Principal Consultant
BIS Research Inc.

3
Agenda
▪ Multi-Modal Approaches to Improve Clinical Biomarker
Interpretation
Key Speaker 2 : Dr. Shibicharkravarthy Kannan
▪ Tumor Agnostic Biomarkers
Key Speaker 3 : Mr. Nitish Kumar Singh
▪ Clinical Biomarkers
▪ Oncology Biomarkers
Insight Monk and Previous Reports
Q&A
Introduction
Key Speaker 1 : Dr. Michael R. Rossi

Multi-Modal Approaches to
Improve Clinical Biomarker
Interpretation and Translational
Science
Dr. Michael R. Rossi, Ph.D., FACMG
VP of Translational Science and Multi-Modal RWE
ConcertAI

Disclosure Statement
• I am an employee of ConcertAI.
• I was formerly employed by Sema4 (now GeneDx).
• The information presented here is not confidential or proprietary
• I have nothing to disclose

Outline
• Historical context of multi-modal precision medicine
• Clinical breast cancer vignette of the importance of clinical
history in interpreting genomics and disease progression

Amplifications
Translocations
Gene mutations

http://www.vicc.org/research/shared/translational/services/snapshot.php
8

SABC 2021: Clinical WTS/WTS vs Oncomine®v3

SABC 2021: Clinical WTS/WTS vs Oncomine®v3
• We identified clinically significant variants in 92% (281/307) of breast
tumors sequenced of which 41% (127/307) were clinically actionable and
13% (17/127) were assigned to therapy
• These numbers are similar to NCI-MATCH: “Assignment rates for NSCLC,
colorectal, breast, and prostate cancer were 17.4%, 13.7%, 17.8%, and
23.0%, respectively.” DOI: 10.1200/JCO.19.03010 Journal of Clinical
Oncology 38, no. 33 (November 20, 2020) 3883-3894.

Patients with Longitudinal FFPE specimens
Acquired ERS1 fusion (Pair 2) and
ESR1 p.Y537C (Pair 5) Fulvestrant
resistance variants

2005: DCIS, 2016: metastatic
1st line: Letrozole + Paobociclib (2016-11 to 2018-01) POD 2nd line: Fulvestrant + Ribociclib (2018-01 to 2018-05) POD
3rd line: Capecitabine (2018-05 to 2018-12) POD 4th line: Tamoxifen (2018-12 to 2019-03) POD
5th line: Paclitaxel (2019-03 to now)
Follow-up Replicates
Days from 1st
Collection
Collection Date
ReportExportDat
e
Tumor/Blast % RSM subtype Stage Variant tag Significant_variants VUS
Yes Pair2 0 11/11/2016 2018-10-08 50 HR+/HER2- IV MDM2 AMP
Yes Pair2 746 11/27/2018 2019-01-04 80 HR+/HER2- IV ESR1 mutation
CDKN2A p.R58*, ESR1
p.Y537S, MDM2 AMP
ESR1 ESR1-
AKAP12
Pair 2

1985: early stage breast cancer, 2018: met
1st line: Fulvestrant + Palbociclib 2021-04: POD 2nd line: Exemestane + Ribociclib (2021-05-05 to 2021-06-30) 2021-06-30: POD 3rd line: Olaparib (2021-07-01 to now)
Follow-up Replicates
Days from 1st
Collection
Collection Date
ReportExportDat
e
Tumor/Blast % RSM subtype Stage Variant tag Significant_variants VUS
Yes Pair5 0 9/26/2018 2019-02-02 20 HR+/HER2- IV
BRCA1
mutation
BRCA1 p.T1122Rfs*10,
FGFR1 Gain
Yes Pair5 954 5/7/2021 2021-05-26 HR+/HER2- IV
BRCA1
mutation, ESR1
mutation
BRCA1 p.T1122Rfs*10, ESR1 p.Y537C,
FGFR1 AMP, MYC AMP
Pair 5

Acknowledgements (Too Many People)
Lab
Dan Sisco
Stephanie McDade
Crina Sanchioni
Lab Directors
Feras Hantash
Hussam Al-Kateb
Leadership
Eric Schadt
Michelle Zimmerman
Oncologists
Amy Tiersten
William Oh
Ken Onel
Tomi Jun
Bioinformatics
Andrew Uzilov
Huan Wang
Jonathan Keeling
Chris Dwan
Data and Software
Rong Chen
Scott Newman
Marc Fink
Zhiqiang (John) Li
Xiang Zhou
Pathologists
Sertac Kip
Wanying Zhang
Kim Cole

Conclusions
• Multi-modal data, combining multiple data points and data types, is
required to understand complex diseases like cancer.
• More emphasis must be placed on clinicogenomics and clinical multi-
omics data to interpret response to therapy and disease progression.
• Future biomarkers will likely be derived by complex datasets.
• Artificial Intelligence (AI) will be most effective as a physician assistant if
the data elements are clear and vetted.

Tumor
Agnostic
Biomarkers
For Tumor Agnostic Therapies

PRECISION ONCOLOGY
BIOMARKERS
S T A T E O F T H E A R T A N D E M E R G I N G T E C H N O L O G I E S
Dr. Shibichakravarthy Kannan, MBBS, PhD
Founder & CEO Oncophenomics Inc.

PRECISION ONCOLOGY BIOMARKERS - WEBINAR
3
Precision Medicine in Oncology
Targeted
Therapies
Immuno-
therapies
• Precision medicine in oncology is a patient-centered approach that aims to customize cancer treatment based
on an individual's unique genetic makeup.
• This approach can potentially improve outcomes and reduce side effects.
• Biomarkers play a critical role in precision oncology, serving as indicators of normal biological processes,
pathogenic processes, or responses to therapeutic interventions.
• Next-generation sequencing (NGS): Enables comprehensive analysis of the cancer genome, leading to the
identification of actionable mutations.
• Liquid biopsies: Non-invasive methods for detecting circulating tumor DNA (ctDNA) and circulating tumor origin
RNA in the form of exosomes (ctRNA) and circulating tumor cells (CTCs) in blood.
Genome
Medicine
Cell-based
therapies

4
PRECISION ONCOLOGY NEEDS PRECISION BIOMARKERS

5
Liquid Biopsy
Emerging Strategies: Single-cell Sequencing
Single-cell sequencing offers the potential to analyze
individual cells within a tumor, providing a more
comprehensive picture of tumor heterogeneity.
Multi-omics, multi-analyte and multi-modal
integration of genomics, epigenomics,
transcriptomics, proteomics, metabolomics, etc., to
provide a more comprehensive understanding of
cancer biology from circulating biomarkers.

6
CIRCULATING TUMOR BIOMARKERS

7
NTRK Gene Fusion
A Key Driver in Multiple Tumor Types
NTRK gene fusions have been found in more than 21 adult and
pediatric solid tumor types
• Colorectal, biliary, pancreatic, and appendiceal.
• Glioma and glioblastoma.
• Mammary analogue secretory carcinoma.
• Infantile fibrosarcoma and soft tissue sarcoma.
TRK FUSION PROTEINS ARE THE KEY
ONCOGENIC DRIVER FOR MANY CANCERS

8
NTRK Gene Fusions Lead to the Formation of Oncogenic TRK Fusion Proteins
• In TRK fusion cancer, the NTRK gene (NTRK1, NTRK2, and NTRK3) fuses with an unrelated gene
• This fusion causes the expression of TRK fusion proteins
• Which results in cell proliferation and tumor growth
How VITRAKVI works in TRK fusion cancer1
• VITRAKVI is highly selective and potent
against the TRK family of proteins (TRKA,
TRKB, and TRKC)
• VITRAKVI was purposefully designed to avoid
activity with off-target kinases
• The only other kinase activity occurred at 100-
fold higher concentrations
• VITRAKVI blocks the downstream signaling
pathway
• This results in inhibition of the tumor growth
and survival that lead to TRK fusion cancer

9
VITRAKVI: THE TRK INHIBITOR EXCLUSIVELY DESIGNED TO ONLY TARGET TRK

10
ACROSS SOLID TUMORS
VITRAKVI®
PROVEN AND
DURABLE EFFICACY
ACROSS TUMOR TYPES
Reference
•VITRAKVI [summary of product characteristics].
Leverkusen, Germany: Bayer AG; 2022.
IRC analysis by RECIST v1.1.
Evaluated per independent review committee analysis by
RECIST v1.1 for all tumor types except patients with a primary
CNS tumor who were evaluated per investigator assessment
using either RANO or RECIST v1.1 criteria.
With 2 complete, 1 partial response.
With 1 complete, 1 partial response.
One patient who is not evaluable.
+ denotes ongoing response.
CNS, central nervous system; DOR, duration of response; IRC,
independent review committee; NA, not applicable due to
small numbers or lack of response; NR; not reached; ORR,
overall response rate; RANO, Response Assessment in Neuro-
Oncology; RECIST, Response Evaluation Criteria in Solid Tumors

11
COMPREHENSIVE GENOMIC PROFILING BY NGS IS PREFERRED OVER IHC
TEST ALL PATIENTS EARLY TO IDENTIFY THOSE
WITH NTRK GENE FUSIONS WHO CAN BENEFIT
FROM VITRAKVI®

12
TAFINLAR, IN COMBINATION WITH MEKINIST FOR BRAF MUTATIONS
INDICATIONS
TAFINLAR, in combination with MEKINIST, is indicated:
•for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test
•for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of
lymph nodes, following complete resection
•for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test
•for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory
locoregional treatment options
•for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who
have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval
based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of
clinical benefit in confirmatory trials
•for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
Limitation of Use: TAFINLAR, in combination with MEKINIST, is not indicated for treatment of patients with colorectal cancer because of known intrinsic
resistance to BRAF inhibition. TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors.

13
RETEVMO FOR PATIENTS WITH RET-ALTERED ADVANCED SOLID TUMORS
Selpercatinib (Retevmo) is a National Comprehensive Cancer Network® (NCCN®)-
recommended treatment option for certain patients with RET-positive metastatic non-
small cell lung cancer (NSCLC) and RET-positive advanced or metastatic thyroid carcinoma
Next-generation sequencing (NGS) can be an accurate and
tissue-efficient method to test for driver RET alterations and
other targetable biomarkers.
• Both RET point mutations and fusions can be detected by NGS
• Immunohistochemistry (IHC) is not preferred for detecting RET alterations
due to low sensitivity and variable specificity
• Test the tissue: molecular testing of FFPE tumor tissue specimens is
preferred for detecting RET fusions and point mutations
• Why NGS? - Broad molecular profiling to identify appropriate targeted
therapies can improve outcomes in NSCLC
• NCCN Guidelines for NSCLC recommend that, when feasible, molecular
testing of NSCLC specimens be performed via a broad, panel-based
approach, most typically performed by NGS
• Because of potential tissue limitations in metastatic NSCLC and the increased
number of actionable biomarkers, NGS testing is part of the most
comprehensive strategy to identify appropriate targeted therapies
• Consider NGS testing to identify the 69% of patients with lung
adenocarcinoma who have a potentially actionable oncogenic driver
alteration and may benefit from appropriate approved or investigational
targeted therapy

14
TESTING FOR RET IS ESSENTIAL TO IDENTIFY PATIENTS WHO MAY BE ELIGIBLE FOR RETEVMO
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend
testing for RET alterations in appropriate patients with advanced and/or metastatic
NSCLC and thyroid carcinoma* to determine if they are eligible for RET inhibitors
such as selpercatinib (Retevmo)
Emerging = biomarkers with therapies under investigation but not approved
Other = unknown oncogenic driver detected
EGFR = EGFR sensitizing mutations including exon 20 insertions
EGFR other = secondary EGFR mutations, including Thr790Met and Cys797Ser,
and other less common EGFR mutations
KRAS other = all KRAS mutations other than KRAS G12C

15
KEYTRUDA® (PEMBROLIZUMAB): PD-1 RECEPTOR BLOCKADE
Normal immune response
When functioning properly, T cells are activated
and can attack tumor cells.
Tumor evasion and T-cell deactivation
Some tumors can evade the immune system
through the PD-1 pathway. The PD-L1 and PD-L2
ligands on tumors can bind with PD-1 receptors
on T cells to inactivate the T cells.
T-cell reactivation with KEYTRUDA
KEYTRUDA binds to the PD-1 receptor and blocks its
interaction with PD-L1 and PD-L2, which helps restore
the immune response. While having an effect on the
tumor, this could also affect normal healthy cells.
Advanced Melanoma or Adjuvant Therapy for Melanoma
Advanced NSCLC or Adjuvant Therapy for Non–Small Cell Lung Cancer (NSCLC)
Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell
Carcinoma (HNSCC)
Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Refractory or Relapsed Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Advanced Urothelial Carcinoma (UC)
High-Risk Non-muscle Invasive Bladder Cancer (NMIBC)
Advanced Gastric or GEJ Cancer
Advanced Esophageal or GEJ Carcinoma
Advanced MSI-H/dMMR Cancers – Tumor Agnostic Therapies
Advanced TMB-H Cancers
Advanced MSI-H/dMMR Colorectal Cancer (CRC)
Advanced Cervical Cancer
Advanced Merkel Cell Carcinoma (MCC)
Adjuvant Treatment for RCC or Advanced Renal Cell Carcinoma (RCC)
Advanced MSI-H/dMMR Endometrial Carcinoma
Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Advanced TNBC or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

16
BIOMARKER TESTING – PD-L1 BY IHC
Understanding PD-L1 Testing:
• PD-L1 expression is evaluated differently depending on the type of cancer
• Combined positive score (CPS) and tumor proportion score (TPS) both evaluate PD-L1 expression and help identify
patients eligible for treatment with KEYTRUDA

17
BIOMARKER TESTING – TMB and MSI BY NGS
MSI-H/dMMR (Microsatellite Instability-
High/Mismatch Repair Deficient)
• Immunohistochemistry (IHC) detects the
presence and absence of MMR protein
expression
• dMMR is defined as at least 1 protein (MSH 2,
MSH 6, PMS 2 and MLH 1) showing loss of
expression
• Next-generation sequencing (NGS) compares the
length of nucleotide repeats in tumor cells and
normal cells
• NGS is a gene sequencing technique used to
identify genetic mutations or variants
Understanding TMB Testing
• Tumor mutational burden (TMB) is an
assessment of the number of somatic mutations
in a defined region of a tumor genome and varies
according to tumor type as well as among
patients.
• Tumors with high levels of TMB are more likely to
produce tumor cell surface epitopes that act as
neoantigens and induce an elevated antitumor
immune response.
• TMB status may be determined using next-
generation sequencing methods. TMB-H may be
a predictive biomarker for response to ICI therapy
in some patients with advanced solid tumors.
MSI-H/dMMR occurs in different solid tumor types, including:
CRC, Endometrial, Gastric or GEJ, Small intestinal, Brain, Ovarian, Biliary, Pancreatic, Sarcoma, Breast, anal, HNSCC,
nasopharyngeal, retroperitoneal, testicular, vaginal, vulvar, appendiceal adenocarcinoma, hepatocellular carcinoma,
carcinoma of unknown origin, and abdominal adenocarcinoma., Cervical, Neuroendocrine, Prostate, Adrenocortical,
Mesothelioma, Thyroid, Small cell lung, Bladder, Salivary, Renal cell etc.

18
SUMMARY AND KEY TAKE AWAY POINTS
• Tumor agnostic biomarkers and therapies represent a significant paradigm shift in oncology, with the
potential to greatly improve patient outcomes
• Tumor Agnostic Therapies – novel cancer treatments that target specific molecular alterations
irrespective of the type or location of cancer
• Tumor agnostic biomarkers - can identify potential targets for therapy across different types of cancer
• Understanding the function of these biomarkers is crucial to the development of new therapies.
• NGS allows for comprehensive genomic profiling, enabling the detection of these biomarkers
• Regulatory acceptance is crucial for the widespread adoption of tumor-agnostic therapies & biomarkers
• The ethical, access, and cost considerations of tumor-agnostic therapies and genetic testing must be
addressed to ensure equitable patient access
• Patients should be educated and empowered to understand their tumor agnostic treatment options,
including potential benefits and risks
Conclusion:
• Tumor-agnostic biomarkers and therapies offer an exciting direction for cancer care, promising a more
personalized and effective approach to treatment.

19
Precision
Oncology
Needs
Precision
Biomarkers
THANK YOU

Clinical Biomarkers
in Oncology
Emerging Tech Webinar
May 2023

Key Speaker
Nitish Kumar
Singh
Principal Consultant
BIS Research Inc.

Clinical
Biomarkers:
Trends and Key
Market
Developments

22
Role of Biomarkers in Role of Biomarkers in Personalized Cancer Treatment
Biomarkers Provide Valuable Information about the Characteristics and Behavior of a Tumor
Applications of Biomarkers
in PCT
Prognosis
Diagnosis
Pharmacodynamics
/ Kinetics
Prediction
Likeliness of Recurrence
Helps in Assessing
Individual's risk for developing cancer
Aid in early detection
Determine prognosis
Guide treatment decisions

23
Overview of the Challenges in Biomarker Identification and Validation
Challenges in
Biomarker
Identification and
Validation
Inability to identify
low expression
level biomarkers in
abnormal cancer
growth and normal
cellular growth
Challenging to
distinguish
between a potential
biomarker and a
reliable biomarker
that can be
universally used.
The genetic and
regulatory networks
for individual
patients will differ
significantly, thus
creating a challenge
in identification of
robust biomarkers.
No governing body
with the authority
to revoke the use of
a biomarker in
clinical practice if it
has been shown to
be invalid
Validation of
scientific
justification behind
biomarkers.
High cost of
biomarker validation
assays

24
Regional Market Landscape: Clinical Biomarkers
Market adoption rates across regions and clinical area indicate a high-growth market
10.7 11.8
18.8
28.1
6.2
6.8
10.5
15.2
2.7
3.1
5.1
8.1
0.8
0.9
1.2
1.5
2021 2022 2027 2032
$Billion
North America Europe
Asia-Pacific Latin America and Middle East
CAGR (2022-2032): 8.73%
42.04%
28.94%
11.44%
6.30%
4.50%
3.21%
3.56%
Oncology Biomarker Cardiac Biomarker
Neurological Biomarker Infectious Disease Biomarker
Immunological Biomarker Non-Invasive Prenatal Testing
Other Clinical Areas
2021
Market Size: $21.3 Billion
40.10%
29.75%
11.68%
6.33%
4.51%
3.25%
4.38%
2032
Source: BIS Research Analysis Source: BIS Research Analysis

25
Technological Landscape
Market adoption rates across regions and clinical area indicate a high-growth market
Source: BIS Research Analysis
Benefits of NGS for clinical diagnostics and biomarker
testing in oncology
Technology adoption for clinical biomarkers
31.28%
26.37%
18.19%
13.90%
10.26%
2021
Next Generation Sequencing
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
Enzyme-Linked Immuno Sorbent Assay (ELISA)
Other Technologies
34.34%
27.11%
16.88%
12.25%
9.42%
2032

26
Leading Players in the Market
Service Provider
Product Manufacturers
Market Share > 7%
Market Share in the
Range of 5%-7%
Market
Share < 5%
Market Share > 7%
Market Share in the
Range of 5%-7%
Market
Share < 5%

Clinical
Biomarkers
Market
Dynamics

28
Factors Propelling the Demand for Oncology Biomarkers Facilitating the Understanding
of Progression and Early Diagnosis of a Disease
The Rising Rate of Cancer has been a Key Catalyst in the Growing Demand
Increasing Demand of Clinical
Biomarkers
Increasing Prevalence of Cancer
and Infectious Diseases
16.5%
Nearly half of oncology studies and
16.5% of all trials incorporate
biomarkers
4.5 M
COVID-19 alone caused around
4.5 million deaths in 2020
Rising Key Player Initiatives
6.67%
Key players initiatives of clinical
biomarkers increased 6.67%
between 2020 and 2021

29
Main Applications of Clinical Biomarkers include Liquid Biopsy and Early Cancer Testing
There are currently 4,901 active oncology-based biomarker clinical
trials going on according to clinicaltrials.gov. They can be classified
according to cancer types as shown in table below.
Non-Small Cell Lung Cancer or Small Cell Lung Cancer Survival Rates
Depending on the Stage of Diagnosis
NSCLC or SCLC 2 Year Survival Rate 5 Year Survival Rate
Stage IA1 97% 90%
Stage IA2 94% 85%
Stage IA3 92% 80%
Stage IB 89% 73%
Stage IIA 82% 65%
Stage IIB 76% 56%
Stage IIIA 65% 41%
Stage IIIB 47% 24%
Stage IIIC 30% 12%
Stage IVA 23% 10%
Stage IVB 10% 0%
Note: NSCLC = Non-Small Cell Lung Cancer and SCLC = Small Cell Lung Cancer
Source: Web-MD
14.66%
10.69%
6.32%
5.13%
4.35%
3.00%
1.99%
1.95% 0.81%
51.10%
Breast
Lung
Prostate
Pancreatic
Ovarian
Stomach
Liver
Colon and Rectm
Skin
Others
Need for Early Cancer Detection
Source: Clinicaltrials.gov

30
Rising Detection and Better Management of Cancer is now Possible with Biomarkers
Cancers and Their Most Common Biomarker Tests
Prevalence vs. Age-Standardized Death Rate of Cancer Globally,
2010-2019 (%)
Increasing Cancer Prevalence
-9.89%
-10.86%
-11.85%
-12.82%
-13.63%
-13.98%
-14.52%
-15.21%
-15.28%
-15.22%
-15.18%
-15.72%
-16.23%
1.22%
1.23%
1.24%
1.26%
1.27%
1.29%
1.31%
1.31%
1.32%
1.33%
1.35%
1.36%
1.38%
-20.00% -15.00% -10.00% -5.00% 0.00% 5.00%
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Prevalence (% Share) Age-Standardised Cancer Death Rate (%)
Cancer Types Biomarker Tests
Non-Small Cell Lung
Cancer
Changes in genes such as EGFR, KRAS, ALK, RET, ROS1,
MET, and BRAF
Breast Cancer
Progesterone receptor (PR) and Estrogen receptor (ER)
proteins; changes in genes such as BRCA1, BRCA2, and
PIK3CA; HER2 gene or protein status
Colorectal Cancer Changes in genes such as NRAS, KRAS, and BRAF
Melanoma Skin Cancer Changes in the BRAF gene
Any Cancer
Changes in NTRK genes; changes in mismatch repair (MMR)
genes; tumor mutational burden (TMB); levels of microsatellite
instability (MSI)
Source: American Cancer Society
Source: Ourworldindata.org

32
8.9 9.8
12.8
21.7
2021 2022 2025 2032
Market
Size
and
Growth
Market Size ($ Bn)
Oncology Biomarkers: Size, Growth, Trends
Key Trends:
▪ Illumina, Inc. launched the TruSight genomic profiling test to assess tumor genes across approximately 30 types of solid tumors
▪ QIAGEN N.V. partnered with Denovo Biopharma to develop a companion diagnostic test for the treatment of diffuse large B-cell lymphoma
(DLBCL).
▪ NeoGenomics Laboratories partnered with the Biomarker Collaborative to ensure patients receive comprehensive biomarker testing and
support access to clinical trials.
CAGR (2022-2032): 8.27% 35.50%
27.29%
18.63%
10.78%
7.79%
Breast Cancer Biomarker Lung Cancer Biomarker
Colorectal Cancer Biomarker Prostate Cancer Biomarker
Other
2021
37.11%
28.10%
19.66%
9.11%
6.02%
2032

33 www.bisresearch.com I All right reserved
Insight Monk
▪ Over 1,000+ healthcare industry market intelligence reports
▪ Access to PDFs from over 100,000 reputed sources
▪ Market Statistics
▪ Company profiles for leading and emerging companies in the healthcare industry
▪ Database of key industry professionals
▪ Expert content like analyst notes, whitepapers
▪ Global expert network for consultations
To get a free trial access, please schedule a demo. Visit: https://www.insightmonk.com/

34
Related Reports, Links and Promotions
Related Reports from BIS Research
Clinical Biomarkers - A Global and Regional Analysis
Published: 2022
View Report Details
Liquid Biopsy Market
Published: 2022
View Report Details
Global Digital Biomarkers Market - A Global and Regional Analysis
Published: 2022
View Report Details
www.bisresearch.com

35
Liquid Biopsy: An Emerging Frontier in
Early Multicancer Detection
Speaker Contact Information
Dr. Michael R. Rossi
Reach out to him at
mirossi@concertai.com
Nitish Kumar Singh
Reach out to him at
nitish.kumar@bisresearch.com
www.bisresearch.com
Dr. Shibicharkravarthy Kannan
Reach out to him at
skannan@oncophenomics.com

37
14 Green Hydrogen and Green Fuels – The Future of Energy www.bisresearch.com I All right reserved
BIS RESEARCH INC.
39111 Paseo Padre Pkwy STE 313, Fremont CA 94538-1686, USA
T
el: +1-510-404-8135
BIS RESEARCH PRIVATE LIMITED
Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303 India
Tel: +91 120 4261540
www.bisresearch.com
THANK YOU

Webinar by BIS Research on Precision Oncology Biomarkers

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Webinar by BIS Research on Precision Oncology Biomarkers

Similar to Webinar by BIS Research on Precision Oncology Biomarkers (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Webinar by BIS Research on Precision Oncology Biomarkers